Diabetic Med:1型和2型糖尿病住院和出院时的用药错误

2017-11-30 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于1型和2型糖尿病住院和出院时的用药错误的研究。以评估1型和2型糖尿病患者出入院时用药错误的发生率和特征,并确定这些错误的潜在风险因素。

近日,国际杂志 《Diabetic Med》上在线发表一项关于1型和2型糖尿病住院和出院时的用药错误的研究。以评估1型和2型糖尿病患者出入院时用药错误的发生率和特征,并确定这些错误的潜在风险因素。 前瞻性观察研究包括2013年至2015年期间在法国蒙彼利埃大学医院糖尿病科入院的1型糖尿病(n=163)和2型糖尿病(n=508)患者。药师在入院24小时内和出院时进行了药物对照。从不同来源(患者/家属访谈,处方/医疗记录,与社区药房/全科医生/护士的接触)收集用药史并与入院和出院处方进行比较,以检测药物治疗中的无意识差异。用药错误被定义为由医生纠正的无意识的用药差异。使用逻辑回归进行评估用药错误和严重错误(即可能造成伤害的错误)的风险因素。 研究共发现用药错误322起,主要是遗漏。入院时1型和2型糖尿病患者用药错误率分别为21.5%和22.2%,出院时分别为9.0%和12.2%。在校正年龄和治疗次数后, 1型糖尿病患者发生用药错误(OR 1.72,95%置信区间(CI)1.02-2.94)和严重错误的几率(OR 2.17, 95%可信区间为1.02-4.76)是2型糖尿病患者几乎两倍。 研

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1772838, encodeId=8b9f1e7283812, content=<a href='/topic/show?id=539369e122c' target=_blank style='color:#2F92EE;'>#用药错误#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69712, encryptionId=539369e122c, topicName=用药错误)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e66138418826, createdName=jml2022, createdTime=Tue Aug 28 17:53:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970550, encodeId=83d419e055031, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Apr 30 11:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760369, encodeId=f1bf1e60369a4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 02 21:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638224, encodeId=df42163822453, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 12 06:53:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608302, encodeId=25f11608302fb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 02 10:53:00 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1772838, encodeId=8b9f1e7283812, content=<a href='/topic/show?id=539369e122c' target=_blank style='color:#2F92EE;'>#用药错误#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69712, encryptionId=539369e122c, topicName=用药错误)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e66138418826, createdName=jml2022, createdTime=Tue Aug 28 17:53:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970550, encodeId=83d419e055031, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Apr 30 11:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760369, encodeId=f1bf1e60369a4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 02 21:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638224, encodeId=df42163822453, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 12 06:53:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608302, encodeId=25f11608302fb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 02 10:53:00 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1772838, encodeId=8b9f1e7283812, content=<a href='/topic/show?id=539369e122c' target=_blank style='color:#2F92EE;'>#用药错误#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69712, encryptionId=539369e122c, topicName=用药错误)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e66138418826, createdName=jml2022, createdTime=Tue Aug 28 17:53:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970550, encodeId=83d419e055031, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Apr 30 11:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760369, encodeId=f1bf1e60369a4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 02 21:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638224, encodeId=df42163822453, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 12 06:53:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608302, encodeId=25f11608302fb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 02 10:53:00 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1772838, encodeId=8b9f1e7283812, content=<a href='/topic/show?id=539369e122c' target=_blank style='color:#2F92EE;'>#用药错误#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69712, encryptionId=539369e122c, topicName=用药错误)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e66138418826, createdName=jml2022, createdTime=Tue Aug 28 17:53:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970550, encodeId=83d419e055031, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Apr 30 11:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760369, encodeId=f1bf1e60369a4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 02 21:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638224, encodeId=df42163822453, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 12 06:53:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608302, encodeId=25f11608302fb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 02 10:53:00 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1772838, encodeId=8b9f1e7283812, content=<a href='/topic/show?id=539369e122c' target=_blank style='color:#2F92EE;'>#用药错误#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69712, encryptionId=539369e122c, topicName=用药错误)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e66138418826, createdName=jml2022, createdTime=Tue Aug 28 17:53:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970550, encodeId=83d419e055031, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Apr 30 11:53:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760369, encodeId=f1bf1e60369a4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 02 21:53:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638224, encodeId=df42163822453, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 12 06:53:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608302, encodeId=25f11608302fb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 02 10:53:00 CST 2017, time=2017-12-02, status=1, ipAttribution=)]

相关资讯

Diabetic Med:预混与餐时胰岛素治疗2型糖尿病哪个更好?

近日,国际杂志 《Diabetic Med》上在线发表一项关于预混与餐时胰岛素治疗2型糖尿病的随机对照试验和普通数据临床结果比较的研究。通过随机对照试验(RCT)得出的数据与普通数据比较2型糖尿病患者餐时胰岛素与预混胰岛素2治疗4周后HbA 1c和体重变化,并对两种方法进行比较。

中国2型糖尿病合并血脂异常防治专家共识(2017年修订版)

2型糖尿病(T2DM)患者合并血脂异常,可进一步增加大血管和微血管并发症的风险[1]。为了进一步做好T2DM患者的血脂管理工作,中华医学会内分泌学分会曾于2011年颁布了《中国2型糖尿病合并血脂异常防治专家共识》[2]。近年来,一系列新研究结果的发表、新指南的颁布,促使了血脂异常管理理念进一步发展。为了进一步优化我国T2DM患者的血脂管理,为临床医生提供更为科学合理的诊疗建议,中华医学会内分泌学分

J Gastroenterol Hepatol:腰臀比是2型糖尿病患者肝脂肪变性和纤维化发生风险的独立预测指标

较高的WCR与不依赖胰岛素抵抗的NAFLD和肝纤维化的风险增加有关。这表明,WCR可能是一项有用的预测2型糖尿病患者肝脂肪变性发生风险的指标。

Diabetic Med:年轻2型糖尿病患者一级亲属转化为糖尿病的风险较高

近日,国际杂志 《Diabetic Med》上在线发表一项关于年轻2型糖尿病患者一级亲属转化为糖尿病的高风险12年的随访分析的研究。 糖尿病家族史是2型糖尿病的一个确定的危险因素,但年轻糖尿病家族史(发病年龄<40岁)对一级亲属未来糖尿病风险的影响尚不清楚。在这项前瞻性研究中,研究人员研究了晚发型和年轻型糖尿病家族史对中国中青年糖尿病发展的影响。

CFDA批准上市安达唐®(达格列净片)审评概述,用于2型糖尿病成年患者的血糖控制

达格列净片(Dapagliflozin,商品名:安达唐/ FORXIGA)是一种高度选择性的钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,其作用机制不依赖于胰岛素,而是通过抑制SGLT2,减少滤过葡萄糖的重吸收,降低葡萄糖的肾阈值,从而增加尿糖排泄。本次在我国批准用于2型糖尿病成年患者的血糖控制,规格为5mg、10mg,推荐起始剂量为5 mg每日一次。对于需加强血糖控制且耐受5 mg每日一次的患者

Diabetes Obes Metab:2型糖尿病:口服降糖药中加入Gla-100 哪些因素影响临床结局?

2017年11月,发表在《Diabetes Obes Metab》的一项研究调查了患者特征和不同口服降糖药物(OAD)的使用对起始使用甘精胰岛素100?U/mL(Gla-100)的2型糖尿病患者标准化临床结局的影响。